- Home
- NFBK vs ARCT Comparison
NFBK vs ARCT Comparison
Compare NFBK & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- ARCT
- Stock Information
- Founded
- NFBK 1887
- ARCT 2013
- Country
- NFBK United States
- ARCT United States
- Employees
- NFBK N/A
- ARCT N/A
- Industry
- NFBK Major Banks
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- ARCT Health Care
- Exchange
- NFBK Nasdaq
- ARCT Nasdaq
- Market Cap
- NFBK 496.7M
- ARCT 320.8M
- IPO Year
- NFBK 2007
- ARCT N/A
- Fundamental
- Price
- NFBK $11.88
- ARCT $19.62
- Analyst Decision
- NFBK Buy
- ARCT Strong Buy
- Analyst Count
- NFBK 2
- ARCT 10
- Target Price
- NFBK $13.00
- ARCT $50.88
- AVG Volume (30 Days)
- NFBK 157.6K
- ARCT 503.6K
- Earning Date
- NFBK 10-22-2025
- ARCT 11-06-2025
- Dividend Yield
- NFBK 4.54%
- ARCT N/A
- EPS Growth
- NFBK 28.89
- ARCT N/A
- EPS
- NFBK 0.86
- ARCT N/A
- Revenue
- NFBK $133,079,000.00
- ARCT $122,122,000.00
- Revenue This Year
- NFBK $8.04
- ARCT N/A
- Revenue Next Year
- NFBK $23.35
- ARCT $28.92
- P/E Ratio
- NFBK $13.28
- ARCT N/A
- Revenue Growth
- NFBK 4.86
- ARCT N/A
- 52 Week Low
- NFBK $9.40
- ARCT $8.04
- 52 Week High
- NFBK $14.39
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- NFBK 56.11
- ARCT 67.57
- Support Level
- NFBK $11.30
- ARCT $17.70
- Resistance Level
- NFBK $11.99
- ARCT $19.50
- Average True Range (ATR)
- NFBK 0.28
- ARCT 1.09
- MACD
- NFBK -0.04
- ARCT 0.01
- Stochastic Oscillator
- NFBK 69.05
- ARCT 98.01
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.